GenFleet Therapeutics (Shanghai) Inc. (GENFLEET-B; HKEX: 02595) repurchased 135,000 H-shares on 8 October 2026 through on-market transactions, spending HKD 3.83 million.
The repurchases were executed at prices ranging between HKD 27.80 and HKD 28.74 per share, translating into a volume-weighted average price of approximately HKD 28.38.
Following the transaction, the company’s issued share capital (excluding treasury shares) declined by 0.04% to 350.51 million shares, while treasury shares on hand rose to 1.12 million. The total share count (including treasury shares) remained unchanged at 351.63 million.
The buyback was conducted under a mandate approved on 11 May 2026, which authorises GenFleet-B to repurchase up to 37.04 million shares. Cumulative repurchases under this mandate now stand at 1.12 million shares, equivalent to 0.30% of the issued share base at the mandate date.
In accordance with Hong Kong Stock Exchange rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 7 November 2026.
Joint Company Secretary Zhang Wei confirmed that all repurchases complied with the HKEX Main Board Rules and that no material changes have occurred in the company’s previously filed explanatory statement.
Comments